575 results on '"Tatsugami, Katsunori"'
Search Results
2. Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
3. Development of Robotic Urologic Surgery in Asia
4. Relationship between body composition and hormone sensitivity for androgen deprivation therapy in patients with metastatic prostate cancer
5. Prognostic significance of diabetes mellitus and dyslipidemia in men receiving androgen-deprivation therapy for metastatic prostate cancer
6. A multicenter retrospective study of nivolumab monotherapy in previously treated metastatic renal cell carcinoma patients: interim analysis of Japanese real-world data
7. Genome-wide association study of genetic variations associated with treatment failure after intravesical bacillus Calmette–Guérin therapy for non-muscle invasive bladder cancer
8. Genetic Polymorphism in Sex Hormone-binding Globulin With a Prognosis of Androgen Deprivation Therapy in Metastatic Prostate Cancer Among Japanese Men
9. Clinical Outcomes in Patients With Metastatic Papillary Renal-Cell Carcinoma: A Multi-Institutional Study in Japan
10. Correction to: Prognostic value of programmed death-ligand 1 status in Japanese patients with renal cell carcinoma
11. Neoadjuvant androgen-deprivation therapy with radical prostatectomy for prostate cancer in association with age and serum testosterone
12. The Association of Polymorphisms in the Gene Encoding Gonadotropin-Releasing Hormone with Serum Testosterone Level during Androgen Deprivation Therapy and Prognosis of Metastatic Prostate Cancer
13. Assessment of surgical skills by using surgical navigation in robot-assisted partial nephrectomy
14. The impact of genetic polymorphism on CYP19A1 in androgen-deprivation therapy among Japanese men
15. Real-world treatment outcomes of patients with penile cancer in the Kyushu–Okinawa area of Japan in the pre-guideline era
16. Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
17. Progression to bone-marrow carcinomatosis and extraosseous legion during treatment with radium-223 for multiple bone metastases
18. Table S1 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
19. Supplementary Table 1 from Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer
20. Figure S6 from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
21. Supplementary Data from Foxo3a Suppression of Urothelial Cancer Invasiveness through Twist1, Y-Box–Binding Protein 1, and E-Cadherin Regulation
22. Supplementary Table 2 from Inhibition of Protein Kinase C/Twist1 Signaling Augments Anticancer Effects of Androgen Deprivation and Enzalutamide in Prostate Cancer
23. Legends for supplementry figures from Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity
24. Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan
25. The Differential Impact of Body Mass Index and the Feature of Metabolic Syndrome on Oncological Outcomes Following Different Surgical Procedures in Japanese Men with Prostate Cancer
26. A case report of primary malignant melanoma of male urethra with distinct appearance in multiple regions
27. Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
28. Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus
29. Nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan
30. Reality of nerve sparing and surgical margins in surgeons’ early experience with robot‐assisted radical prostatectomy in Japan
31. Suppressed Recurrent Bladder Cancer after Androgen Suppression with Androgen Deprivation Therapy or 5α-Reductase Inhibitor
32. Significance of prostate-specific antigen-related factors in incidental prostate cancer treated by holmium laser enucleation of the prostate
33. The oncological outcome and validation of Japan Cancer of the Prostate Risk Assessment score among men treated with primary androgen-deprivation therapy
34. Methyltransferase Inhibitor Adenosine Dialdehyde Suppresses Androgen Receptor Expression and Prostate Cancer Growth
35. Androgen Receptor Signaling Regulates Cell Growth and Vulnerability to Doxorubicin in Bladder Cancer
36. Antioxidant Therapy Alleviates Oxidative Stress by Androgen Deprivation and Prevents Conversion From Androgen Dependent to Castration Resistant Prostate Cancer
37. Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer
38. Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer
39. CROSSTALK BETWEEN EPITHELIAL-MESENCHYMAL TRANSITION AND CASTRATION RESISTANCE IN PROSTATE CANCER: MP62-20
40. CLINICAL OUTCOMES IN PATIENTS WITH METASTATIC PAPILLARY RENAL CELL CARCINOMA: A JAPANESE MULTI-INSTITUTIONAL STUDY: MP03-13
41. Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era
42. Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy
43. MP69-19 EXTENDED ANALYSES OF PHASE II CLINICAL TRIAL OF SORAFENIB PLUS INTERFERON-ALPHA TREATMENT FOR PATIENTS WITH METASTATIC RENAL CELL CARCINOMA IN JAPAN
44. MP46-11 TARGETING RIBOSOMAL S6 KINASES/Y-BOX BINDING PROTEIN-1 SIGNALING IMPROVES CELLULAR SENSITIVITY TO TAXANE IN PROSTATE CANCER
45. Pathological manifestation of difference in washout pattern of adrenal hyperplasia on dynamic CT
46. YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α
47. Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
48. The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy
49. The Oncological Outcomes and Risk Stratification in Docetaxel Chemotherapy for Castration-resistant Prostate Cancer
50. Inhibition of RSK/YB-1 signaling enhances the anti-cancer effect of enzalutamide in prostate cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.